INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Paper

AI in Drug Discovery

Boomisha S. D.*, Jemmy Christy H.

Department of Bioinformatics, Sathyabama institute of science and technology, Chennai, Tamil Nadu

ARTICLE INFO

Published: 22 Feb. 2025
Keywords:
Artificial Intelligence, Drug Discovery, Machine Learning, Structure – based drug design, Ligand – based drug design
DOI:
10.5281/zenodo.14907864

ABSTRACT

Artificial intelligence (AI) is the technology and science of creating intelligent machines by using algorithms which the machine adheres to in order to mimic human cognitive functions like learning and problem solving. Artificial intelligence (AI) is the term used to describe computer programs that simulate the mechanisms that support the intellect of humans, including as engagement, deep learning, reasoning, adaptation, and sensory comprehension. It aims to mimic human cognitive functions. This article examines the prospective applications of AI in drug discovery, emphasizing significant developments and their possible effects. Target identification is being expedited by AI-driven predictive modeling, which is also expediting the identification of prospective medication candidates. An expedient and economical substitute for conventional drug development is provided by AI's capacity to mine data for drug repurposing. Artificial Intelligence enhances patient recruiting and trial management in clinical trials, leading to better efficiency and results. The combination of AI with large data and omics technology is yielding new insights, and in silico testing is predicting the safety and effectiveness of pharmaceuticals. Collaborative platforms driven by AI are also accelerating research and promoting open innovation. This paper highlights the enormous influence artificial intelligence (AI) is expected to have on drug discovery, with the potential to produce novel and efficient treatments that would significantly improve global healthcare.

INTRODUCTION

Artificial intelligence (AI) has started to be used more extensively in society recently, with the pharmaceutical industry setting the standard for its advantages. In many respects, artificial intelligence (AI) has changed the pharmaceutical sector. The pharmaceutical business benefits from AI help across the whole life cycle of the product. AI has several applications in the pharmaceutical industry, from developing new medications to managing existing ones. The application of artificial intelligence (AI) is growing across

***Corresponding Author:** Boomisha S. D.
Address: *Department of Bioinformatics, Sathyabama institute of science and technology, Chennai, Tamil Nadu*
Email ✉: boomidhamodharan@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

various domains in society, chief among them being the pharmaceutical industry. This paper emphasizes the use of AI in the pharmaceutical business, with applications spanning from clinical trials, medication repurposing, and development and discovery to increased pharmaceutical production. These apps reduce the amount of labour that needs to be done by humans while also accelerating objective attainment [1]. Because computer-assisted design of drugs has a chance to expedite and reduce the expenses of the process of developing drugs, there is a great deal to explore in this emerging discipline. The process of finding new medicines is expensive and time-consuming; it usually takes ten to fifteen years for a drug to be commercialized. This field of study has been significantly impacted by CADD. Additionally, these technologies are used to handle enormous amounts of biological data has reduced the time and cost associated with the drug development process.

AI in Pharmaceutical Products

It is appropriate to imagine artificial intelligence (AI) having an effect in the creation of a medicine from the laboratory bench to the hospital because AI may assist with rational formulate drugs, support making choices, identify the most appropriate course of therapy for a patient, which includes customized pharmaceuticals, and manage the produced medical information to use it to guide subsequent drug development. Marketing professionals can get help from the quantitative and the making of choices AI platform E-VAI in deciding where to invest, turning around underperforming revenue, and assigning resources for the greatest increase in market share. The method creates predictive directions based on rivals, important stakeholders, and holds market share to forecast major trends in pharmaceutical sales. It does this by utilizing technologies in conjunction with a user-friendly interface [2].

Process of Drug Discovery

For a molecule to possess any kind of therapeutic value, it needs to be "druggable." The focus of drug development in the post-genomic age has switched, in order to develop newer drugs in the future, fundamental principles of design to molecules or new methods to bind, control, or destroy challenging biological targets. Historically, the pharmaceutical industry has concentrated on creating tiny compounds that are orally accessible and have predetermined targets, sometimes known as druggable targets. In accordance with Ro5, if the molecular weight is greater than 500 Da, there are a minimum of five hydrogen-bond donors (HBD > 5), as well as greater over ten hydrogen-bond acceptors, there is a greater chance of poor absorption or penetration. Since then, while developing developable compounds for drug discovery, Ro5 has been used as guidance. Although there has been some success in finding small molecule Ro5 drugs that interact with known "druggable" targets, there is a growing need for innovation to engage additional targets for transformational treatments. Therefore, from the beginning in the drug-discovery process, discovering and validating novel biological targets has taken centre stage. Historical data supports the application of AI and DL in this domain. Additionally, cutting-edge methods for data mining, curation, and management offer crucial backing for freshly created modeling algorithms. Identification of medicinal product targets, confirmation of targets, production of hits to leads, and optimization of the lead, both preclinical and clinical research are all steps in the drug research and development process [3][4].

Drug Designing

Drug discovery is the process of applying computational aspects, experimental in nature & clinical frameworks to identify potential new medicinal entities. The search for novel therapies remains a very difficult, time-consuming, expensive, and inefficient process with few new

therapeutic discoveries, despite advances in technologies and the comprehension of biological mechanisms. Drug creation is the process of developing novel pharmaceuticals by utilizing a target in biology. In the simplest sense, drug design is the creation of molecules with complementary shapes and charges to the molecular target with which they interact and bind. In the big data era, bioinformatics methods and computational modeling techniques are often, but not always, used in drug design [5]. Preclinical research on animal and cell models, as well as human clinical trials, are all part of the process of developing and discovering new drugs. Afterward, the drug must receive regulatory approval before being put on the market. Finding screening hits, improving medicinal chemistry, and boosting the drug's effectiveness, stability in metabolic processes, oral accessibility, affinity, selectivity, and efficiency are every requirement in the process of developing new medications. Before conducting clinical trials, a molecule that satisfies all of these criteria will be found, and the drug development process will start [6].



Fig 1: Pipeline of Drug Discovery [15]

One of the most important phases in the drug discovery process is the identification of molecules by testing compound collections using primary assays, like high through-put screening in vitro, and secondary assays, like counter-screens and ADMET (absorption, distribution, metabolism, excretion, and toxicity) studies. Structure–activity relationship (SAR), in computational research, and intracellular functional testing are used in an iterative cycle to improve the functional properties of the therapeutic candidates. Organic synthesis is used to produce novel drug candidates with desired characteristics. The selected drug candidate, which has now effectively finished all preclinical testing, is given to human subjects in a clinical study.

Types of Drug Designing

It is expected that computational techniques will be crucial in comprehending the distinct molecular recognition events of the target macromolecule, as candidate hits will aid in the creation of better leads for the target. Computer-aided pharmaceutical design (in silico) approaches have been widely used in the lead discovery and optimized lead discovery stages of the development of medicines against many targets over the years. Using rational drug design methodologies instead of traditional drug discovery procedures shortens the time and costs involved in the medication development process. The process can be applied to de novo identification and to create new inhibitors or to optimize the distribution, metabolism, excretion, absorption, and toxicity profile of compounds that

have been found from different sources [7]. Developments in technology and computational approaches have made it easier to use in silico methods for discovery. These are two types: Ligand-based drug design (LBDD) and Structure-based drug design (SBDD) [7].



Fig 2: Basic principles and types of drug design [8].

Structure – based drug design

This method known as SBDD uses the drug receptor's knowledge to create an inhibitor of the target. The most popular methods for determining the structure of a receptor are experiments like NMR or X-ray crystallography. If one does not know the structure of the protein therapeutic target, one can utilize computational approaches like homology simulation and threading to anticipate the protein structure. Technique termed threading, or fold, is used to simulate proteins in the absence of protein structures. The steps involved in homology modeling proteins are as follows: Identifying homologous proteins with known three-dimensional structures that could serve as templates; aligning the sequences of the target and template proteins; building a target model based on the template's three-dimensional arrangement and alignment; and validating and improving the model. When crystal structures are unavailable, modeling homology has become the main alternative to get a three-dimensional image of the target over time [9].

De Novo Pharmaceutical Design

The Latin word "de novo" means "from the beginning". The structural characterization of a drug target's active site will reveal information about its binding characteristics. It is possible to create ligands that are specifically tailored to a target by using the makeup orientation. For de novo design techniques, computational tools that can identify possible chemicals and study the active site of proteins are widely used. These are the following steps:

Techniques for locating fragments: To pinpoint the ideal positions of atoms or tiny pieces inside the activeregion.

Methods for connecting site points: Identifying specific places, or "site points," inserting fragments into the active site to occupy those spots with the right atoms.

Methods for connecting pieces: After placing the fragments, "linkers" "scaffolds", join them and maintain their intended alignment.

Methods for sequential buildup: Assemble a ligand piece by piece or atom by atom.

Whole molecule techniques: Different conformations of compounds are inserted into the active site to evaluate shape and/or electrostatic complementarily. A unique class of approaches known as randomized connection methods combines elements of sequential building and

fragment connection techniques with bond disconnection tactics and randomness-inserting procedures [10]. Many de novo techniques, particularly whole molecule techniques like docking, have been incorporated throughout time into computer modeling, chemistry, pharmacology, and molecular biology. Calculating electrostatic and salvation terms, which are essential for determining accurate binding energies, can be challenging and time-consuming. The complexity of algorithms is increasing, yielding ever-better estimates for certain parameters. Lastly, it is evident from the most recent research that the drug design process is now a crucial component of drug development initiatives [10].

Virtual Screening using Structure

One popular strategy for the lead identification stage is virtual screening, which is a supplement to test screening at high rates in a research study in order to increase the productivity and speed of the drug discovery and development process. This entails scoring and detailed molecular docking of each ligand to the target binding site. The chemicals in the screened databases are ordered in order to identify and test experimentally a limited subset for biological activity deemed suitable for a particular receptor. Numerous effective uses of molecular docking-based virtual screening have been documented. With the aim of enhancing the faster and efficacy of the process of finding and developing drugs, virtual screening is being employed more frequently in conjunction with high-throughput screening [11].



Fig 3: A basic drug discovery workflow using CADD [12].

Ligand – Based Drug Design

In the absence of 3D models of possible therapeutic targets, widely used method for lead selection and to find possible drug. These techniques can offer valuable information about the type of interactions that occur between the ligand and drug target as well as predictive models that are appropriate for lead compound optimization. With CADD methodologies, drug design can be achieved on both ligand- and structure-based approaches. When there isn't an experimental three-dimensional structure available. Since there is presently no empirical structure associated with these ligands, the known ligand particles that bound to the therapeutic target are analyzed in order to understand the structural and physical features of the ligands that match with the anticipated therapeutic properties of those ligands. For ligand-based approaches, natural products or substrate equivalents that bind with the molecule being studied and deliver the intended pharmaceutical effect can also be used instead of well-known ligand molecules [13].

QSAR

The QSAR method modelling technique is used for ligand-based drug design. The association between a certain biological action is determined using a computer method known as QSAR.

Similar structural or physicochemical features result in similar activity, according to the fundamental hypothesis of the QSAR technique. First, a group of substances known as lead molecules are found to possess the necessary biological capacity of interest. The developed QSAR model is then used to maximise the active compounds in order to achieve the greatest appropriate biological properties.

The intended activity of the anticipated chemicals is next investigated experimentally [13].

The foundation of the generic QSAR technique consists of the following steps:

1. Determine which ligands have the desired biological activity at values obtained from experiments.
2. Find and identify the molecular designations associated with the various structural and properties of the molecules under investigation.
3. Determine the connections between descriptors of molecules and activity in biology that explain the difference in activity shown in the information set.
4. Analyze the prediction effectiveness and analytical reliability of the QSAR techniques model.



Fig 4: Workflow of QSAR [13]

In conclusion, developments in AI and DL offer a great chance for a logical approach to medication design and discovery that will eventually benefit humanity.

AI in Drug Designing

Computers to assist drug development has been propelled by artificial intelligence. This pattern is being filled in by advances in computer software and hardware as well as the growing application of machine learning, especially deep learning, in many scientific domains. The initial doubt that started to dissipate about the application of AI in the development of drugs has been advantageous. Deep learning has seen a relatively late comeback, but it has already resulted in an unparalleled proliferation of new modeling techniques and applications. Deep learning's constant advancements have already proven beneficial to many branches of the chemical sciences. Through examples, this opinion piece outlines some of the factors that have facilitated the growth of deep learning methodologies and, in certain situations,

have even outperformed the state-of-the-art cheminformatics approaches. Specifically, structure-based modelling, de novo molecular design, synthesis prediction, and ligand-based quantitative structure-activity/property relationship (QSAR/QSPR) are covered.

Novel deep learning approaches, which are the foundation of ligand-based drug development, may make it easier to find new chemical entities. Deep learning approaches that include chemical knowledge and incorporate multidimensional patterns into their creation show promise for conformation-aware and structure-based modeling. Integration based on rules and rule-free approaches enhance artificial intelligence's capacity to produce synthesizable bioactive compounds and discover uncharted chemical space. Multitasking, meta-learning, and explainable AI will open the door for a new class of prediction models that perform well in low-data regimes and are easier to understand. Models of natural language processing will be widely used for forward synthesis prediction as well as retro synthesis. Further work will be focused on associated issues including reaction condition prediction. Some basic issues in drug development have only recently started to be addressed by deep learning-based methods. Some of the most difficult challenges will probably be solved with the help of methodological advancements such as hybridized new-generation design, other methodologies. The development of artificial intelligence-powered drug discovery will depend heavily on the development of models and the free sharing of data. [14].



Fig 5: Comparison of Classical and Modern method [14]

Fig 6: Comparison of Synthesis planning of classical and modern [14]

AI in Primary Drug Screening

When analyzing large amounts of data, the process of identifying images by standard visual inspection

becomes extremely time-consuming and inefficient. In order to classify or diagnose cell targets, the model is taught quickly to recognize the many characteristics of cell kinds. For instance, by adjusting the image contrast, the images of the cells are separated from the backdrop in order to categories lung cancer cells. Following the extraction of wavelet-based and Tamura texture characteristics, principal component analysis is utilized for minimizing the derived properties. Afterwards, AI-based techniques are trained to categories various cell kinds. The least-square support vector machine (LS-SVM) approach, which uses regression and classification techniques and is based on statistical learning theory, is one of the evaluated methods. AI has recently been applied to computerized electrocardiography (ECG) interpretation in addition to cell recognition and classification. This is an important step in the processes involved in clinical diagnosis and treatment. Additionally, the laborious procedure of manual checking by a skilled practitioner is simpler. Deep learning (DL) algorithms and widely accessible digital ECG data can significantly increase the precision and the computerized ECG evaluation's adaptability [15] [26].

AI - 3-D Structure of Protein

The accuracy and complexity of predicting the structure of a target protein has increased with the emergence of AI-based techniques. AlphaFold predicted 25 out of 43 structures correctly using only primary sequences of proteins. Compared to the contestant in second place, who accurately predicted only three out of forty-three test sequences, these results were much better. Using DNNs trained to infer protein attributes from its basic sequence, AlphaFold operates. It forecasts the separations between amino acid pairs φ–ψ between the adjacent. A score is then created by combining these two probabilities, and this score is used to determine how accurate a suggested 3D protein structure model is. AlphaFold searches the landscape of protein structures using these scoring methods to identify structures that agree with standards [15] [16]. Deep analysis is now possible thanks to the development of artificial intelligence (AI) systems, which include supercomputing systems, the use of the most sophisticated algorithms, huge data generated by high-throughput techniques, and access to enormous digital medical records. with deep learning and machine learning techniques, altering the dynamic clinical research [17].

Prediction of The Retro Synthesis Pathway Using AI

Retro synthesis is a complex method of producing organic synthesis. AI advancement has made it possible to complete this task much more quickly. The biological function and tolerability profile of a molecule are virtually assessed prior to identifying the most effective chemical production method that would produce an effective treatment possibility. This stage is usually challenging and unproductive. It is not certain that unique molecules can be effectively synthesized due to novel structural features or paradoxical reactivities [15].

Advantages and Uses Of AI

Artificial intelligence (AI) is utilized to manage digital health records, determine clinical conditions in healthcare imaging and testing facilities, control the COVID-19 outbreak with prompt detection, find unique drugs and immunizations, identify healthcare prescription inaccuracies and provide ample information storage and analysis. AI-powered instruments are also being used to provide online medical attention for patients and improve patient participation and compliance to therapy regimens. However, this science pitch tackles a number of technical, legal, and social difficulties related to embedding AI into healthcare, such as privacy, safety, liberty to choose and try, costs, information and consent,

access, and efficacy. The safety and accountability of patients, as well as the belief of healthcare professionals in improving acceptability and boosting major health repercussions, all depend on the regulation of AI applications. To accurately handle ethical, trust, and regulatory challenges while pushing AI adoption and deployment, effective governance is a must. The idea of AI has revolutionized healthcare since the global health system was hit by COVID-19, and this revolution could be an additional move toward satisfying subsequent medical demands [18] [28]. AI's effects on ways of thinking are investigated, as well as the application and constraints of AI in medication. While artificial intelligence (AI) can significantly support the initial phases of the creation of drugs, and direction should still be given top priority, AI need to be seen as an advantage rather than a crucial factor. [31]. By predicting the biological activity of possible medicinal molecules, AI systems can cut down on the amount of time needed for trial-and-error testing. Artificial intelligence (AI)-powered systems can quickly design and create novel compounds, which speeds up the process of finding viable treatment candidates. Drug repurposing, a technique where artificial intelligence analyses current pharmaceutical data to identify new applications for already-approved medications, can be quicker and less expensive than creating new medications from the ground up. By examining genetic data and medical records, AI can find qualified participants for clinical trials, making the process more successful and efficient. Clinical trial management and design can be optimised by AI, which can also anticipate results and spot possible problems before they happen [19] [20]. The discovery of knowledge can be aided by natural language processing (NLP), which can be used to evaluate scientific literature in order to extract important information, spot trends, and develop predictions [21] [22] [23].

CONCLUSION

Artificial intelligence (AI) technologies facilitate better decision-making by making use of the readily available, excellent information, which saves time and money [25] [27]. Recently, a number of machine learning techniques have emerged; some of these could be seen as examples of domain-specific AI that has been effectively applied to drug design and discovery [29]. AI advancements in other domains and focused research will both be advantageous for the use of research. future years will see a further increase in the use of AI in drug discovery due to the combination of algorithmic breakthroughs and high-quality data [30] [31]

REFERENCES

1. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21. PMID: 33099022; PMCID: PMC7577280.
2. Blasiak A. CURATE. AI: optimizing personalized medicine with artificial intelligence. SLAS Technol. 2020; 25:95–105.
3. Sarkar C, Das B, Rawat VS, Wahlang JB, Nongpiur A, Tiewsoh I, Lyngdoh NM, Das D, Bidarolli M, Sony HT. Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. Int J Mol Sci. 2023 Jan 19;24(3):2026. doi: 10.3390/ijms24032026. PMID: 36768346; PMCID: PMC9916967.
4. Mason J.S. Introduction to the volume and overview of computer assisted drug design in the drug discovery process. In: Taylor J.B., Triggle D.J., editors. Comprehensive

Medicinal Chemistry II. Elsevier; Amsterdam, The Netherlands: 2007. pp. 1–11.

5. Luu K.T., Kraynov E., Kuang B., Vicini P., Zhong W.Z. Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies. AAPS J. 2013; 15:551–558. doi: 10.1208/s12248-013-9464-8.
6. Zhou SF, Zhong WZ. Drug Design and Discovery: Principles and Applications. Molecules. 2017 Feb 13;22(2):279. doi: 10.3390/molecules22020279. PMID: 28208821; PMCID: PMC6155886.
7. Shaikh SA, Jain T, Sandhu G, Latha N, Jayaram B. From drug target to leads-sketching a physicochemical pathway for lead molecule design in silico. Curr. Pharm. Design. 2007;13(34):3454–3470.
8. Aparoy P, Reddy KK, Reddanna P. Structure and ligand-based drug design strategies in the development of novel 5- LOX inhibitors. Curr Med Chem. 2012;19(22):3763-78. doi: 10.2174/092986712801661112. PMID: 22680930; PMCID: PMC3480706.
9. Kroemer RT. Structure-based drug design: Docking and scoring. Curr. Protein Pept. Sc. 2007;8(4):312–328.
10. Murcko MA. In: Reviews in Computational Chemistry. Lipkowitz KB, Boyd DB, editors. Vol. 11. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2007. pp. 1–67.
11. Ghosh S, Nie A, An J, Huang Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol. 2006 Jun;10(3):194-202. doi: 10.1016/j.cbpa.2006.04.002. Epub 2006 May 3. PMID: 16675286.
12. Yu W, MacKerell AD Jr. Computer-Aided Drug Design Methods. Methods Mol Biol. 2017; 1520:85-106. doi: 10.1007/978-1-4939-6634-9_5. PMID: 27873247; PMCID: PMC5248982.
13. Acharya C, Coop A, Polli JE, Mackerell AD Jr. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des. 2011 Mar;7(1):10-22. doi: 10.2174/157340911793743547. PMID: 20807187; PMCID: PMC2975775.
14. Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov. 2021 Sep;16(9):949-959. doi: 10.1080/17460441.2021.1909567. Epub 2021 Apr 2. PMID: 33779453.
15. Chan HCS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing Drug Discovery via Artificial Intelligence. Trends Pharmacol Sci. 2019 Aug;40(8):592-604. doi: 10.1016/j.tips.2019.06.004. Epub 2019 Jul 15. Erratum in: Trends Pharmacol Sci. 2019 Oct;40(10):801. doi: 10.1016/j.tips.2019.07.013. PMID: 31320117.
16. Aumentado-Armstrong, T. (2018) Latent molecular optimization for targeted therapeutic design. arXiv Published online September 5, 2018.
17. Khan SR, Al Rijjal D, Piro A, Wheeler MB. Integration of AI and traditional medicine in drug discovery. Drug Discov Today. 2021 Apr;26(4):982-992. doi: 10.1016/j.drudis.2021.01.008. Epub 2021 Jan 18. PMID: 33476566.
18. Al Kuwaiti A, Nazer K, Al-Reedy A, Al-Shehri S, Al-Muhanna A, Subbarayalu AV, Al Muhanna D, Al-Muhanna FA. A Review of the Role of Artificial Intelligence in Healthcare. J Pers Med. 2023 Jun 5;13(6):951. doi: 10.3390/jpm13060951. PMID: 37373940; PMCID: PMC10301994.
19. Javaid M., Haleem A., Singh R.P., Suman R., Rab S. Significance of machine learning in

healthcare: Features, pillars and applications. Int. J. Intell. Networks. 2022; 3:58–73. doi: 10.1016/j.ijin.2022.05.002.

20. Bajwa J., Munir U., Nori A., Williams B. Artificial intelligence in healthcare: Transforming the practice of medicine. Future Healthcare J. 2021;8:e188–e194. doi: 10.7861/fhj.2021-0095.
21. Tran B.X., Vu G.T., Ha G.H., Vuong Q.-H., Ho M.-T., Vuong T.-T., La V.-P., Ho M.-T., Nghiem K.-C.P., Nguyen H.L.T., et al. Global Evolution of Research in Artificial Intelligence in Health and Medicine: A Bibliometric Study. J. Clin. Med. 2019; 8:360. doi: 10.3390/jcm8030360. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
22. Jiang F., Jiang Y., Zhi H., Dong Y., Li H., Ma S., Wang Y., Dong Q., Shen H., Wang Y. Artificial intelligence in healthcare: Past, present and future. Stroke Vasc. Neurol. 2017; 2:230–243. doi: 10.1136/svn-2017-000101.
23. Iroju O.G., Olaleke J.O. A Systematic Review of Natural Language Processing in Healthcare. Int. J. Inf. Technol. Comput. Sci. 2015; 7:44–50. doi: 10.5815/ijitcs.2015.08.07.
24. Vemula D, Jayasurya P, Sushmitha V, Kumar YN, Bhandari V. CADD, AI and ML in drug discovery: A comprehensive review. Eur J Pharm Sci. 2023 Feb 1; 181:106324. doi: 10.1016/j.ejps.2022.106324. Epub 2022 Nov 5. PMID: 36347444.
25. Pasrija P, Jha P, Upadhyaya P, Khan MS, Chopra M. Machine Learning and Artificial Intelligence: A Paradigm Shift in Big Data-Driven Drug Design and Discovery. Curr Top Med Chem. 2022;22(20):1692-1727. doi: 10.2174/1568026622666220701091339. PMID: 35786336.
26. Mak K.-K., Pichika M.R. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today. 2019; 24:773–780.
27. Fleming N. How artificial intelligence is changing drug discovery. Nature. 2018;557 S55–S55.
28. Yang X. Concepts of artificial intelligence for computer-assisted drug discovery. Chem. Rev. 2019; 119:10520–10594.
29. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chem Rev. 2019 Sep 25;119(18):10520-10594. doi: 10.1021/acs.chemrev.8b00728. Epub 2019 Jul 11. PMID: 31294972.
30. Walters WP, Barzilay R. Critical assessment of AI in drug discovery. Expert Opin Drug Discov. 2021 Sep;16(9):937-947. doi: 10.1080/17460441.2021.1915982. Epub 2021 Apr 19. PMID: 33870801.
31. Lv Q, Zhou F, Liu X, Zhi L. Artificial intelligence in small molecule drug discovery from 2018 to 2023: Does it really work? Bioorg Chem. 2023 Dec; 141:106894. doi: 10.1016/j.bioorg.2023.106894. Epub 2023 Sep 27. PMID: 37776682.

HOW TO CITE: Boomisha S. D.*, Jemmy Christy H., AI in Drug Discovery, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 2, 1800-1810. https://doi.org/10.5281/zenodo.14907864